GlaxoSmithKline prescribes commercial reboot for pharma division

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/22/2026

1. META
2. TSLA
3. IBM
4. TXN
5. LVS
6. SAP
7. CSX
8. LRCX
9. KNX
10. ELV

Go back to GlaxoSmithKline prescribes commercial reboot for pharma division

Pfizer (PFE) Announces Top-Line Results from Study of CHANTIX/CHAMPIX (varenicline) in Adolescent Smokers

March 23, 2018 8:01 AM EDT

Pfizer Inc. (NYSE: PFE) announced today results from a Phase 4 study evaluating the efficacy and safety of CHANTIX®/CHAMPIX® (varenicline) for smoking cessation in nicotine dependent adolescents 12-19 years of age. The study did not meet its primary endpoint of the four-week continuous abstinence rate at weeks 9 through 12 for CHANTIX/CHAMPIX compared to placebo. The study is a regulatory post marketing commitment for CHANTIX/CHAMPIX in the U.S. and EU for adolescents 12-16 years and 12-17 years of age, respectively.

This study makes a valuable contribution to the limited body of clinical research on... More